Journal profile · Medicine-Oncology
Molecular Therapy-Oncolytics
ISSN 2372-7705 · Cell Press · UNITED STATES
Molecular Therapy-Oncolytics: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.03; fully open access; APC about USD 3,900; review about 6 weeks (community reports); 144 articles a year; indexed in Scopus.
Scope
Aims, scope and focus
Molecular Therapy-Oncolytics is published by Cell Press and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Virus-based gene therapy research, CAR-T cell therapy research and Immunotherapy and Immune Responses, together about 42% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Molecular Therapy — Oncolytics is an international, online-only, open access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer.
Source: LetPub
Research area (LetPub): Medicine-Oncology
Editor-in-chief Timothy CripePublisher website
Editorial board by country: none in mainland China; most named United States 16, Japan 2, Hong Kong, China 1, France 1, Spain 1 (26 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology19.8%
- CAR-T cell therapy researchMedicine16.1%
- Immunotherapy and Immune ResponsesImmunology and Microbiology6.1%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.1%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.6%
- Viral Infectious Diseases and Gene Expression in InsectsBiochemistry, Genetics and Molecular Biology4.4%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology4.1%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.03LetPub ·
- CiteScore 2026-06
- 10.9LetPub ·
- SJR 2026-06
- 1.49LetPub ·
- SNIP 2026-06
- 0.86LetPub ·
- h-index
- 12LetPub ·
- h-index
- 69OpenAlex ·
- i10-index
- 674OpenAlex ·
- 2-year mean citedness
- 0OpenAlex ·
- Share of gold OA articles
- 89.58%LetPub ·
Volume
- Articles per year
- 144LetPub ·
Articles by year OpenAlex count · 820 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2023 | 93 | 93 | 1,145 |
| 2022 | 140 | 140 | 3,620 |
| 2021 | 189 | 189 | 5,973 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 6 weeksLetPub ·
- Submission to publication (journal-reported)
- about 6 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,900 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,900 / EUR 3,490 / GBP 3,120 / JPY 438,200 | — | — | |
| LetPub | USD 3,900 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Cell Press
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 2372-7705
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Molecular Therapy-Oncolytics
What CAS zone is Molecular Therapy-Oncolytics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Molecular Therapy-Oncolytics is in Zone 2 of Medicine, and in Zone 3 of the minor category Medicine, Research & Experimental / Oncology. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular Therapy-Oncolytics?
The latest impact factor listed by LetPub is 6.03; CiteScore 10.9, h-index 69.
How long does peer review take at Molecular Therapy-Oncolytics?
Authors report an average review time of about 6 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Molecular Therapy-Oncolytics based?
Of the 26 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (16), Japan (2) and Hong Kong, China (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Molecular Therapy-Oncolytics?
According to LetPub and DOAJ records, Molecular Therapy-Oncolytics is indexed in Scopus and DOAJ.
Is Molecular Therapy-Oncolytics open access, and what is the APC?
Molecular Therapy-Oncolytics is a fully open-access journal. APC about USD 3,900.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .